Pre‐morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis | Zendy

Pagai Sabrina | Zendy; Hyman Theodore | Zendy; Shui Amy | Zendy; Allred Peggy | Zendy; Harms Matthew | Zendy; Liu Jingxia | Zendy; Maragakis Nicholas | Zendy; Schoenfeld David | Zendy; Yu Hong | Zendy; Atassi Nazem | Zendy; Cudkowicz Merit | Zendy; Miller Timothy M. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Pre‐morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis

Author(s) -

Pagai Sabrina,

Hyman Theodore,

Shui Amy,

Allred Peggy,

Harms Matthew,

Liu Jingxia,

Maragakis Nicholas,

Schoenfeld David,

Yu Hong,

Atassi Nazem,

Cudkowicz Merit,

Miller Timothy M.

Publication year - 2015

Publication title -

muscle and nerve

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.025

H-Index - 145

eISSN - 1097-4598

pISSN - 0148-639X

DOI - 10.1002/mus.24688

Subject(s) - amyotrophic lateral sclerosis , medicine , body mass index , diabetes mellitus , risk factor , type 2 diabetes , population , clinical endpoint , type 2 diabetes mellitus , proportional hazards model , hazard ratio , multivariate analysis , clinical trial , disease , confidence interval , endocrinology , environmental health

The aim of this study was to determine whether a history of pre‐morbid type 2 diabetes mellitus (DM2) is a prognostic factor in amyotrophic lateral sclerosis (ALS). Methods: The relationship between DM2 and survival was analyzed in a study population consisting of 1,322 participants from 6 clinical trials. Results: Survival did not differ by diabetes status (log‐rank test, P = 0.98), but did differ by body mass index (BMI) (log‐rank test, P = 0.008). In multivariate analysis, there was no significant association between diabetes and survival ( P = 0.18), but the risk of reaching a survival endpoint decreased by 4% for each unit increase in baseline BMI (HR 0.96, 95% CI 0.94–0.99, P = 0.001). DM2 was less prevalent among ALS clinical trial participants than predicted. Conclusions: A history of pre‐morbid DM2 is not an independent prognostic factor in ALS clinical trial databases. The low DM2 prevalence rate should be examined in a large, prospective study to determine whether DM2 affects ALS risk. Muscle Nerve 52:339–343, 2015

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research